Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Share-based Compensation (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Share-based Compensation over the past 12 years, most recently at -$32.3 million for Q4 2025.

  • Quarterly results put Share-based Compensation at -$32.3 million for Q4 2025, down 460.04% from a year ago — trailing twelve months through Sep 2025 was $41.3 million (down 56.38% YoY), and the annual figure for FY2024 was $42.2 million, down 37.25%.
  • Share-based Compensation for Q4 2025 was -$32.3 million at Viridian Therapeutics, Inc.\DE, down from $11.2 million in the prior quarter.
  • Over the last five years, Share-based Compensation for VRDN hit a ceiling of $61.5 million in Q4 2023 and a floor of -$32.3 million in Q4 2025.
  • Median Share-based Compensation over the past 5 years was $4.9 million (2022), compared with a mean of $6.2 million.
  • Biggest five-year swings in Share-based Compensation: crashed 514.98% in 2022 and later surged 1158.3% in 2024.
  • Viridian Therapeutics, Inc.\DE's Share-based Compensation stood at $3.5 million in 2021, then crashed by 514.98% to -$14.5 million in 2022, then soared by 524.37% to $61.5 million in 2023, then plummeted by 85.4% to $9.0 million in 2024, then crashed by 460.04% to -$32.3 million in 2025.
  • The last three reported values for Share-based Compensation were -$32.3 million (Q4 2025), $11.2 million (Q3 2025), and $10.8 million (Q2 2025) per Business Quant data.